Brought to you by 
Shire licenses rights to galanthamine from Synaptec
13 Jul 1999
Executive Summary
Shire Pharmaceuticals has received exclusive worldwide development rights outside NAFTA countries, Japan and 4 other Asian nations, from Synaptec to galanthamine, an acetylcholinesterase inhibitor for treating Alzheimer's.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire licenses rights to galanthamine from Synaptec
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice